Tyra Biosciences, Inc.

TYRA | $16.355 5.52% 5.23% 150K

(0.0% 1d) (-5.9% 1m) (22.9% 1y) (0.0% 2d) (0.0% 3d) (7.3% 7d) (-68.3% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 859,027,567
https://tyra.bio
Sec Filling | Patents | 2021 employees

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Tyra is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. Tyra is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Tyra's lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.

treatment cancer optical

add to watch list Paper trade email alert is off

Press-releases

Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
Published: 2024-03-19 (Crawled : 20:00) - prnewswire.com
TYRA | $16.355 5.52% 5.23% 150K

Health Technology

| -3.73% | O: 9.38% H: 0.0% C: -1.36%
year financial results

Tyra Biosciences to Present at Upcoming Investor Conferences
Published: 2024-02-27 (Crawled : 21:00) - prnewswire.com
TYRA | $16.355 5.52% 5.23% 150K

Health Technology

| -21.2% | O: 0.05% H: 5.03% C: 1.12%

Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-07 (Crawled : 23:00) - biospace.com/
TYRA | $16.355 5.52% 5.23% 150K

Health Technology

| -13.89% | O: -0.22% H: 2.9% C: 0.22%
conference life sciences

Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
Published: 2024-02-02 (Crawled : 13:00) - prnewswire.com
TYRA | $16.355 5.52% 5.23% 150K

Health Technology

| 19.14% | O: 12.61% H: 17.41% C: 14.81%
million

Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia
Published: 2024-02-01 (Crawled : 23:00) - prnewswire.com
TYRA | $16.355 5.52% 5.23% 150K

Health Technology

| 19.14% | O: 12.61% H: 17.41% C: 14.81%
tyra-300 fda rare disease achondroplasia treatment designation

Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300
Published: 2023-12-22 (Crawled : 14:00) - prnewswire.com
TYRA | $16.355 5.52% 5.23% 150K

Health Technology

| 13.3% | O: 1.39% H: 2.67% C: -3.03%
tyra-200 first positive tyra-300

Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference
Published: 2023-11-08 (Crawled : 21:00) - prnewswire.com
TYRA | $16.355 5.52% 5.23% 150K

Health Technology

| 29.17% | O: 1.5% H: 2.63% C: -4.43%
conference

Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
Published: 2023-11-07 (Crawled : 00:00) - biospace.com/
TYRA | $16.355 5.52% 5.23% 150K

Health Technology

| 21.09% | O: -0.31% H: 2.45% C: -4.7%
financial results

Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings
Published: 2023-09-21 (Crawled : 15:30) - biospace.com/
TYRA | $16.355 5.52% 5.23% 150K

Health Technology

| 11.59% | O: -0.72% H: 1.52% C: 0.36%
tyra-300 achondroplasia

Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference
Published: 2023-09-12 (Crawled : 20:00) - prnewswire.com
TYRA | $16.355 5.52% 5.23% 150K

Health Technology

| 5.87% | O: 0.07% H: 3.75% C: 0.82%
conference global

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000950170-24-033845	4	2024-03-19	2024-03-15	Buy	A	1968	86435
0000950170-24-033814	4	2024-03-19	2024-03-15	Buy	A	1880	1504577
0000950170-24-030932	4	2024-03-13	2024-03-11	Sell	S	200	431683